0000000000936800

AUTHOR

Olumide Olatubosun Rowaiye

showing 2 related works from this author

Treatment and its side effects in ANCA-associated vasculitides - Study based on POLVAS registry data.

2020

Abstract Purpose The aim of this study is to present the treatment modalities and associated side effects in a Polish nation-wide ANCA-associated vasculitides (AAV) patients’ cohort. Materials and methods Retrospective analysis of patients diagnosed with AAV between 1990 and 2016, included in the POLVAS registry was performed. Standard descriptive statistic methods were used with an emphasis on the treatment modalities. Results There were 625 patients diagnosed with AAV included in this study: 417 cases of granulomatosis with polyangiitis (GPA; 66.7%), 106 cases of microscopic polyangiitis (MPA; 17.0%) and 102 cases of eosinophilic granulomatosis with polyangiitis (EGPA; 16.3%). The mean ag…

AdultMalemedicine.medical_specialtyCyclophosphamideDrug-Related Side Effects and Adverse ReactionsAzathioprineAnti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis03 medical and health sciences0302 clinical medicineMaintenance therapyInternal medicineAzathioprinemedicineHumansTreatment complications030212 general & internal medicineRegistriesAdverse effectCyclophosphamideGlucocorticoidsANCA associated vasculitisRetrospective Studiesbusiness.industryVasculitis registryGeneral MedicineMiddle Agedmedicine.diseasePrognosisSurvival RateMethotrexate030220 oncology & carcinogenesisCohortRituximabDrug Therapy CombinationFemalePolandMicroscopic polyangiitisGranulomatosis with polyangiitisbusinessRituximabVasculitis treatmentImmunosuppressive Agentsmedicine.drugFollow-Up StudiesAdvances in medical sciences
researchProduct

Anti-ETAR and suPAR as markers of disease activity in renal ANCA-associated vasculitis.

2020

Purpose In anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), there is a lack of reliable biomarkers of disease activity. The aim of the study was to evaluate soluble urokinase plasminogen activator receptor (suPAR) and anti-endothelin-1 type A receptor (anti-ETAR) antibodies levels in active phase and remission of AAV. Patients and methods We enrolled 60 patients (median age 63.0 years) with renal AAV into this study. Plasma suPAR, urine suPAR (expressed as urine suPAR/creatinine ratio) and serum anti-ETAR antibodies were assayed by ELISA. Disease activity was assessed using Birmingham Vasculitis Activity Score (BVAS) and patients were divided into 2 subgroups based o…

Vasculitismedicine.medical_specialtyBirmingham Vasculitis Activity ScoreAnti-Neutrophil Cytoplasmic Antibody-Associated VasculitisUrineKidneyGastroenterologysuPARAntibodies Antineutrophil CytoplasmicReceptors Urokinase Plasminogen Activatorchemistry.chemical_compoundInternal medicineMedicineHumansReceptorCreatinineKidneybiologybusiness.industryANCAGeneral MedicineMiddle Agedmedicine.diseaseReceptor Endothelin Amedicine.anatomical_structurechemistrySuPARbiology.proteinAntibodybusinessVasculitisBiomarkersAdvances in medical sciences
researchProduct